However, this rule does not apply to all targets of Osterix, as Col 1a which has a single binding site is activated, not repressed, by Osterix, while Nell-1 with multiple sites is repressed. Col 1a regulation is more complex, as its regulation has been reported to also involve NFATc1 as a co-factor that forms a complex with Osterix to bind the consensus Sp1 binding site. It is possible that NFATc1 may modulate Osterix-mediated transactivation by recruitment of other transcriptional co-activators. Most recently, another co-factor of Osterix, NO66, a Jumonji family histone demethylase, has been reported to impair transcriptional activation of Osterix through interaction with the Osterix activation domain. In particular, the interaction between Osterix and NO66 is believed to regulate Osterix target genes in osteoblasts through modulating histone methylation. Osterix transcriptional repression of Nell-1, a gene expressed preferentially in osteoblasts, may therefore also involve a co-factor leading to the negative effect on NELL-1 promoter activity. Runx2 is known as the master regulator of osteochondrogenesis, promoting commitment, clonal expansion, and early osteoblastic differentiation, and is a direct upstream regulator of NELL1 gene expression. Our previous studies have demonstrated that Runx2 directly activates NELL-1 transcription by physically binding to OSE2 sites on its promoter region. In this current study, reporter system assays confirmed that Osterix directly represses Runx2-induced NELL-1 expression through binding of multiple Sp1 sites on its promoter. Mechanistically, by using CHIP-qPCR assay, we were able to demonstrate that there was no difference in Runx2 binding of NELL-1 promoter OSE2 sites with and AbMole Tolclofos-methyl without Osterix forced expression. This demonstrates that Osterix-mediated down-regulation of NELL-1 expression does not involve disruption of Runx2 binding of the NELL-1 promoter OSE2 sites. Instead, we found that general transcription factor RNA polymerase II binding to the NELL-1 promoter is significantly decreased when Osterix is overexpressed, which may interfere with initiation of NELL-1 gene transcription. However, the exact role Osterix plays, along with RNA polymerase II, in the negative regulation of NELL-1 with and without Runx2 induction remains unclear and warrants further study. AbMole Chlorothiazide Notably, there has been no evidence to date that Osterix and Runx2 interact with each other directly to alter their DNA binding and promoter transactivating activities. We performed in vitro osteoblastic differentiation studies with either overexpression or specific siRNA knockdown of Osterix in Saos2 as well as in normal primary human osteoblast cells. Expectedly, the mRNA expression of NELL-1 was severely inhibited by overexpression of Osterix. Notably, NELL-1 repression was associated with the early transient decrease of Ocn and Opn mRNA indicating some level of impairment of NELL-1 osteoinductive capacity.